CASI Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$3.22M
-0.1
-2.57
$28.54M
224
CASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company is headquartered in Rockville, Maryland and currently employs 224 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products. The firm's product EVOMELA is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. The Company’s pipeline includes CNCT19, BI-1206, CB-5339, CID-103, Octreotide, and Thiotepa. CNCT19 is used for the treatment of patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). CB-5339 is a Valosin-containing protein (VCP/p97) inhibitor focused on VCP/p97 as a target in protein homeostasis, deoxyribonucleic acid (DNA) damage response, and other cellular stress pathways for use in the treatment of patients with various malignancies. Thiotepa is a chemotherapeutic agent used prior to certain allogeneic hemopoietic stem cell transplants.
CASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company is headquartered in Rockville, Maryland and currently employs 224 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products. The firm's product EVOMELA is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. The Company’s pipeline includes CNCT19, BI-1206, CB-5339, CID-103, Octreotide, and Thiotepa. CNCT19 is used for the treatment of patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). CB-5339 is a Valosin-containing protein (VCP/p97) inhibitor focused on VCP/p97 as a target in protein homeostasis, deoxyribonucleic acid (DNA) damage response, and other cellular stress pathways for use in the treatment of patients with various malignancies. Thiotepa is a chemotherapeutic agent used prior to certain allogeneic hemopoietic stem cell transplants.
Recently from Cashu
CASI Pharmaceuticals Transitioning to OTC Markets: Pursuing Growth and Investor Engagement Opportunities
### CASI Pharmaceuticals Adjusts Course: Embracing New Opportunities on OTC Markets CASI Pharmaceuticals Inc. is undergoing a strategic transition as it announces its move to the OTC Markets Group fol…
CASI Pharmaceuticals Advances Cancer Treatment Innovations Through Strategic Research and Development
CASI Pharmaceuticals Advances in Oncology with New Drug Developments CASI Pharmaceuticals continues to make significant strides in the field of oncology, with a focus on bringing innovative therapies…
CASI Pharmaceuticals Pursues Strategic Partnerships to Advance Oncology Therapy Development
CASI Pharmaceuticals Explores Strategic Partnerships for Development of Novel Therapies CASI Pharmaceuticals focuses on advancing its oncology pipeline through potential strategic partnerships that co…
CASI Pharmaceuticals Submits NDA for Innovative Oncology Drug, Advancing Cancer Treatment Options
CASI Pharmaceuticals Advances in Oncology with New Drug Application CASI Pharmaceuticals, a biopharmaceutical company focused on innovative therapeutics for oncology, recently announces the submission…